Mesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy PipelineTip Ranks·Jul 30 at 07:49 AMMESO+441.00%
Mesoblast's Ryoncil® generates $36M in net revenues for the quarter and $115M in the first year of launch.Unusual Whales·Jul 29 at 08:00 PMMESO+441.00%
Australian Stocks Trading Below Fair Value Based On Cash FlowsSimplywall·Jul 27 at 06:16 PMLYSDY0.00%MESO+441.00%
3 Founder Led Stocks With Real Management Alignment Investors May Want To WatchSimplywall·Jul 20 at 04:08 PMMESO+441.00%
Founder Led Stocks For Investors Watching Australian Small Caps CloselySimplywall·Jul 16 at 12:08 AMMESO+441.00%
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back PainUnusual Whales·Jul 13 at 07:37 PMMESO+441.00%
Mesoblast (ASX:MSB) Is Up 8.7% After Strong Ryoncil Debut And FDA BLA Milestone - Has The Bull Case Changed?Simplywall·Jul 11 at 08:18 PM
